GLP

Global Partners LP Common Units (GLP) Q3 2026 Earnings Call Transcript

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2026. CEO Commentary “Our third quarter results demonstrate the strength of our integrated liquid energy model, with strong growth in both EBITDA and distributable cash flow year over year,” said Eric Slifka, the Partnership's President and Chief Executive Officer. “Solid execution across our terminal network and Whole.

Global Partners (GLP) could produce exceptional returns because of its solid growth attributes.

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that the Board of Directors of its general partner, Global GP LLC, has declared a cash distribution of $0.7850 per unit ($3.14 per unit on an annualized basis) on all of its outstanding common units for the period from July 1, 2026 through September 30, 2026. The distribution will be paid on November 13, 2026 to unitholders of record as of the close of business on November 9,.

NEWTON, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its third-quarter 2026 financial results before the market opens on Friday, November 6, 2026. At 10:00 a.m. ET, the Partnership will conduct a conference call for investors and analysts hosted by Eric Slifka, President and Chief Executive Officer, Gregory B. Hanson, Chief Financial Officer, and Mark Romaine, Chief Operating Officer. The call can be accesse.

GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.

Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

A new peptide ETF launched today, holding the drugmakers behind GLP-1 weight-loss treatments along with the companies that make and deliver them. Key Takeaways: REX's new fund follows 36 peptide-linked companies, ranging from GLP-1 drugmakers to device and supplement makers.